Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Isotechnika has reported that the International Nonproprietary Name expert committee has accepted the proposed generic name of its lead immunosuppressive drug, ISA247. ISA247 will now be referred to as voclosporin.
Subscribe to our email newsletter
Voclosporin is a next generation calcineurin inhibitor, which recently completed a Phase IIb North American trial for the prevention of kidney rejection following transplantation.
Robert Foster, Isotechnika’s chairman and CEO, said: “This completes the process, in combination with the earlier United States Adopted Names approval, of obtaining a generic name for our lead immunosuppressive drug.”